Background/Aims: In patients with chronic kidney disease (CKD) strict blood pressure (BP) control is reno-protective. However, renal benefits from BP control might depend also on the etiology of CKD. We investigated if maintenance of BP at target is equally effective in subjects with hypertensive nephropathy (HN+) and in those with other nephropathies (HN-). Methods: We evaluated 148 patients with CKD (stages 3-5) in two visits at least 12 months apart. BP was measured both as office BP and 24h ambulatory blood pressure (ABP). Glomerular filtration rate (eGFR) was estimated with CKD-EPI formula. The slope of eGFR variation (Delta eGFR) was calculated as: (eGFR1-eGFR0)/months of follow up. Results: Cohort characteristics were: HN- (n=82) and HN+ (n=66), age (71 +/- 9 vs 74 +/- 9 years; p=0.09); prevalence of diabetes (57 vs 43%; p=0.19); average follow up (19 +/- 7 vs 21 +/- 9 months; p=0.3). HN- and HN+ did not differ regarding both baseline eGFR (34 +/- 18 vs 35 +/- 14 ml/min; p=0.97) and Delta eGFR (0.00 +/- 0.53 vs -0.06 +/- 0.35 ml/min/month, p=0.52). The proportion of patients with BP at target at both visits was similar in HN- and HN+ (office BP: HN- 18% and HN+ 27%; p=0.21; ABP: HN- 42% and HN+ 43; p=0.96). In patients with office BP at target at both visits HN- showed a significant improvement of Delta eGFR respect to HN+ (HN-: 0.240 +/- 0.395 and HN+: -0.140 +/- 0.313 ml/min/month; p=0.026). In patients with office BP not at target HN- and HN+ did not show any difference in Delta eGFR (HN- 0.00 +/- 0.47; HN+ -0.030 +/- 0.420 ml/min/month; p=0.66). ABP was not associated with differences in Delta eGFR either if it was at target (HN- 0.104 +/- 0.383 and HN+ 0.00 +/- 0.476 ml/min/month; p=0.42) or not (HN- -0.057 +/- 0.503 and HN+ -0.092 +/- 0.325 ml/min/month; p=0.87). Conclusion: In patients with CKD and HN+ maintenance of BP targets recommended by current guidelines is less reno-protective than it is in HN-. (C) 2018 The Author(s) Published by S. Karger AG, Basel
Patients with Hypertensive Nephropathy and Chronic Kidney Disease Might Not Benefit from Strict Blood Pressure Control
Villarini, Anna;
2018
Abstract
Background/Aims: In patients with chronic kidney disease (CKD) strict blood pressure (BP) control is reno-protective. However, renal benefits from BP control might depend also on the etiology of CKD. We investigated if maintenance of BP at target is equally effective in subjects with hypertensive nephropathy (HN+) and in those with other nephropathies (HN-). Methods: We evaluated 148 patients with CKD (stages 3-5) in two visits at least 12 months apart. BP was measured both as office BP and 24h ambulatory blood pressure (ABP). Glomerular filtration rate (eGFR) was estimated with CKD-EPI formula. The slope of eGFR variation (Delta eGFR) was calculated as: (eGFR1-eGFR0)/months of follow up. Results: Cohort characteristics were: HN- (n=82) and HN+ (n=66), age (71 +/- 9 vs 74 +/- 9 years; p=0.09); prevalence of diabetes (57 vs 43%; p=0.19); average follow up (19 +/- 7 vs 21 +/- 9 months; p=0.3). HN- and HN+ did not differ regarding both baseline eGFR (34 +/- 18 vs 35 +/- 14 ml/min; p=0.97) and Delta eGFR (0.00 +/- 0.53 vs -0.06 +/- 0.35 ml/min/month, p=0.52). The proportion of patients with BP at target at both visits was similar in HN- and HN+ (office BP: HN- 18% and HN+ 27%; p=0.21; ABP: HN- 42% and HN+ 43; p=0.96). In patients with office BP at target at both visits HN- showed a significant improvement of Delta eGFR respect to HN+ (HN-: 0.240 +/- 0.395 and HN+: -0.140 +/- 0.313 ml/min/month; p=0.026). In patients with office BP not at target HN- and HN+ did not show any difference in Delta eGFR (HN- 0.00 +/- 0.47; HN+ -0.030 +/- 0.420 ml/min/month; p=0.66). ABP was not associated with differences in Delta eGFR either if it was at target (HN- 0.104 +/- 0.383 and HN+ 0.00 +/- 0.476 ml/min/month; p=0.42) or not (HN- -0.057 +/- 0.503 and HN+ -0.092 +/- 0.325 ml/min/month; p=0.87). Conclusion: In patients with CKD and HN+ maintenance of BP targets recommended by current guidelines is less reno-protective than it is in HN-. (C) 2018 The Author(s) Published by S. Karger AG, BaselI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
